Teva announces management succession
Jeremy Levin to become ceo of Teva in May and Rob Koremans will become ceo of Teva Europe in March
Levin has more than 25 years of experience in the global pharmaceuticals industry. He joined Bristol-Myers Squibb in 2007 and has had direct responsibility for strategy, alliances and transactions.
Before joining Bristol-Myers Squibb, Levin was global head of business development and strategic alliances at Novartis from 2003 to 2007. Earlier, he was ceo of Cadus Pharmaceuticals, a company he took public.
Teva’s chairman, Philip Frost, said Levin brings to Teva a wealth of experience and the hands-on skills required to foster the growth of a global pharmaceutical business.
‘His combination of vision, creative energy and an effective team-building management style make him an ideal choice to lead Teva into its next growth phase,’ he said.
Yanai has been president and ceo of Teva since 2007. Prior to joining Teva, he was president and ceo of Makhteshim Agan Industries from 2003 to 2006.
Teva has also announced that Rob Koremans will join the company as president and ceo of Teva Europe in March. He joins the company after serving as ceo of Zentiva and most recently as senior vice president of generic strategy and development at Sanofi-Aventis.
After six years, Gerard van Odijk, Teva Europe’s current president and ceo has decided to step down. In the next few months, Koremans and van Odijk will work closely together to ensure a smooth transition and van Odijk will remain with Teva to support the EU region for the remainder of 2012.
Rob Koremans began his career in 1988 at Sanofi SA. In 1993 he joined the Serono Group and was appointed vice-president, Europe in 1998. From 2007 to 2009, Koremans was ceo of Cryo-Save, a leading European stem cell storage company. He returned to Sanofi in 2009 as senior vice president, Generics Europe, Sanofi-Aventis, and ceo of Zentiva. He was appointed president of Zentiva in July 2010 and later became Sanofi’s senior vice president generic strategy and development.
